
Azitra (AZTR) Stock
Small clinical-stage biotech developing microbiome skin treatments. Here's the price, business snapshot, and what's worth knowing about Azitra in November 2026.
Azitra Inc (AZTR) is a small, clinical-stage biotechnology company developing microbiome-based treatments for dermatological conditions. Investors should know it is a micro-cap issuer (market capitalisation around $2.05M), which typically implies limited liquidity, higher share-price volatility and greater sensitivity to funding and trial outcomes. The company’s work focuses on harnessing skin microbes and biologics to address inflammatory and infectious skin diseases; programmes are early-stage and outcomes remain uncertain. Financial results, regulatory milestones and clinical data can substantially move the share price in either direction. This summary is educational, not investment advice: potential investors should read the company’s filings, consider the high-risk nature of micro-cap biotech, and assess whether such exposure fits their objectives and risk tolerance. Past performance is not a reliable guide to future returns, and value can fall as well as rise.
Why You’ll Want to Watch This Stock
Skin Microbiome Focus
Azitra’s programmes target skin conditions using microbial and biologic approaches — an area of scientific interest, though clinical success is uncertain.
Early-stage Outcomes
Clinical data and regulatory updates can drive sharp moves in the share price; investors should expect high event-driven volatility.
Micro-cap Considerations
With a market cap around $2.05M, liquidity and financing are meaningful risks; suitable only for those comfortable with high-risk investments.